ADVERTISEMENT
A fruit bat in the hands of a researcher
How an Early Warning Radar Could Prevent Future Pandemics
Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.
How an Early Warning Radar Could Prevent Future Pandemics
How an Early Warning Radar Could Prevent Future Pandemics

Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.

Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.

coronavirus, infectious disease

A woman wearing a gray sweater and a bright orange scarf and hat blows her nose vaguely in the direction of the camera. A snowy landscape can be seen behind her.
How Cold Weather May Help You Catch a Cold
Dan Robitzski | Dec 6, 2022 | 3 min read
Warm nasal cells mount stronger defenses against cold-causing coronaviruses and rhinoviruses than those exposed to cooler temperatures, an in vitro experiment finds.
Image of a white cardboard box with a blue vertical stripe on the left side, the word “Apixaban” in blue lettering at the bottom, and a depiction of apixaban’s molecular structure in black.
Blood Thinner Ineffective for COVID-19 Patients: Study
Dan Robitzski | Nov 28, 2022 | 2 min read
A clinical trial finds that the anticoagulant apixaban, which has been prescribed to help COVID-19 patients recover, is ineffective and in rare instances dangerous.
Understanding COVID’s Long Game
Understanding COVID’s Long Game
The Creative Services Team in collaboration with Cayman Chemical | 1 min read
Floyd Chilton and Thomas Bumol shine light on the pathways that SARS-CoV-2 hijacks to cause disease.
A person in a white shirt activates a nasal spray
Oxford-AstraZeneca Nasal COVID-19 Vaccine Falters in Clinical Trial
Dan Robitzski | Oct 11, 2022 | 2 min read
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
A surgical mask next to an open pill bottle that’s toppled over, spilling out red capsules meant to represent vitamin D supplements.
Vitamin D Likely Doesn’t Prevent COVID-19, Studies Find
Dan Robitzski | Sep 9, 2022 | 2 min read
The results from two large clinical trials don't support the idea that supplements of the vitamin bolster immune defenses against SARS-CoV-2.
Approaches to Processing SARS-CoV-2 Samples for RNA Detection
The Scientist Creative Services Team in collaboration with MilliporeSigma | 1 min read
Discover new RNA extraction and purification strategies and how they enable reliable and sensitive viral detection.
the Melbourne skyline with lake in foreground
New Australian Center Will Develop Therapies for Future Pandemics
Shawna Williams | Aug 31, 2022 | 2 min read
Launched with a $172 million philanthropic donation and funds from the state of Victoria, the Melbourne-based research institute aims to construct drug discovery platforms to speed the introduction of new therapies.
Illustration of several warped and stretched analog clocks swirling around a central point.
It’s Not Just You: Lockdowns Had Us Living in “Blursday,” Study Says
Dan Robitzski | Aug 26, 2022 | 6 min read
The Scientist spoke with Maximilien Chaumon about his database showing how COVID-19 related lockdowns warped more 2,800 people’s perception of time.
How Infectious Diseases Affect the Brain
The Scientist | 1 min read
From a loss of taste to dementia, infectious agents cause an array of neurological symptoms.
Anthony Fauci
Anthony Fauci Announces Departure from NIAID, Advisory Roles
Catherine Offord | Aug 22, 2022 | 2 min read
The 81-year-old director says that he will step back from his positions this December, but that he will continue working to advance science and public health.
An illustration of a pregnant women wearing a mask, surrounded by microbes
How COVID-19 Affects Pregnancy
Amanda Heidt | Aug 16, 2022 | 10 min read
Evidence thus far shows that pregnant people infected with SARS-CoV-2 are at higher risk for severe disease and death, as well as complications in their pregnancies.
Fast-Tracking COVID-19 Research
The Scientist Creative Services Team in collaboration with Sartorius Corporation | 1 min read
Identifying molecular targets for SARS-CoV-2 therapeutics.
hourglass with coronaviruses instead of sand
Omicron Half as Likely as Delta to Lead to Long COVID: Study
Christie Wilcox, PhD | Jun 17, 2022 | 2 min read
People who were vaccinated at least six months prior to infection had the lowest risk of lasting symptoms in a UK study.
old-fashioned, black and white alarm clock with words "the end"
Editorial: When Will This Pandemic Officially End?
Bob Grant | Mar 11, 2022 | 4 min read
And does it even matter?
T Cells: A New Hope for Lasting Protection against SARS-CoV-2
The Scientist | 1 min read
Alessandro Sette and Shane Crotty discuss the T cell response to SARS-CoV-2 and the implications for vaccine design and robust immune memory.
Woman waiting in line at the airport, carrying a bag and standing next to two other suitcases. She is wearing a N95 face mask.
SARS-CoV-2 in the Air: What’s Known and What Isn’t
Alejandra Manjarrez, PhD | Feb 18, 2022 | 9 min read
Evidence suggests that COVID-19 is primarily an airborne disease. Yet the details of how transmission occurs are still debated and frequently misunderstood.
Yellow-brown hamster on top of cage with green background
Pet Hamsters Spread SARS-CoV-2 in Hong Kong: Preprint
Natalia Mesa, PhD | Feb 4, 2022 | 2 min read
Scientists linked hamsters in a Hong Kong pet shop to 50 cases of the Delta variant in what appears to be the second documented occurrence of animals infecting people with SARS-CoV-2.
Longitudinal Immune Profiling Reveals Key Immune Signatures Associated with COVID-19
The Scientist | 1 min read
Madhvi Menon will discuss immune profiling of COVID-19 patients and Jyoti Phatak-Sheldon will highlight the use of RNAscope in situ hybridization in SARS-CoV-2 research.
illustration of green viral particles flowing into a person's nostril
First COVID-19 Human Challenge Trial Reveals Uneven Susceptibility
Shawna Williams | Feb 3, 2022 | 2 min read
Only half of volunteers deliberately exposed to SARS-CoV-2 developed an infection. None developed serious symptoms, paving the way for further challenge trials.
ADVERTISEMENT